Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Twin Cities
Tampa Bay news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa Bay
Charlotte news in your inbox
Catch up on the most important stories affecting your hometown with Axios Charlotte
OxyContin pills. Photo: Liz O. Baylen/Los Angeles Times via Getty Images
Purdue Pharma and the Sackler family — both of which are facing legal questions about their involvement in the opioid epidemic — made donations to Tufts University's medical school that may have helped advance their business interests, Stat News reports.
Details: Tufts, for example, allowed a high-ranking Purdue executive who said in 2003 that OxyContin wasn't addictive to lecture in the pain program and receive the title of adjunct associate professor.
- The Massachusetts attorney general has alleged that "Purdue got to control research on the treatment of pain coming out of a prominent and respected institution of learning."
The big picture: Experts told Stat that this isn't necessarily an example of a company buying influence, but instead it points to a larger problem:
- "So much industry money flows to academic institutions, professional societies, and patient advocacy organizations that it’s hard to tease apart what’s a purchase of influence and what’s a marriage of convenience for groups with aligned interests or beliefs," Stat's Andrew Joseph writes.